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The role of macrophages in the toxicity and efficacy of liposomal amphotericin B
(L-Amp B) was studied in a murine aspergillosis model infection. Macrophages and
polymorphonuclear phagocytes (PMN cells) were depleted in the liver and spleen of
mice by the administration of liposome encapsulated dichloromethylene diphospho-
nate. Macrophage depletion had no effect on the lethality of Fungizone, a commer-
cial deoxycholate preparation of Amp B, but significantly increased the lethality of
L-Amp B (P < O01). Macrophage depletion led to an increase in the fungal loads in
the lung, liver and kidney (P < 0-05) and to an increase in the virulence of
aspergillosis (/" < 0-05). Tissue distribution analysis of L-Amp B revealed that in
macrophage/PMN-depleted mice there was a decrease in the concentration of
Amp B in the liver, with concomitant increases in the circulation, spleen and lung,
both in the uninfected and in the infected conditions. The results clearly demonstrate
that depletion of macrophage/PMN cells increases the virulence of aspergillosis, as
well as the toxicity of L-Amp B. Moreover, L-Amp B treatment does not improve
the survival rate of macrophage/PMN-depleted mice subjected to aspergillosis
challenge.
Introduction
Aspergillosis, a common systemic fungal infection, is the major cause of mortality in
immunocompromised hosts (Diamond, Huber & Haudenschild, 1983). Macrophages
play an important role in the defence against fungal pathogens by an effective
elimination of the spores in their conidial stage (Schaffner, Douglas & Braude, 1982).
Studies have shown that Aspergillus fumigatus spores phagocytosed by macrophages in
vitro, as well as in vivo after intravenous administration are rapidly removed by the
reticuloendothelial system (Schaffner et al., 1982).
Amphotericin B (Amp B) is the drug of choice for the treatment of systemic fungal
infections such as aspergillosis, but its use is restricted due to severe toxicity. Liposomal
intercalation of the drug offers an effective means both to reduce its toxicity and
improve the therapeutic index when given to control systemic fungal infections (Taylor
et al., 1982; Lopez-Berestein, 1987; Ahmad, Sarkar & Bachhawat, 1989a). We and
others have shown that most of the intravenously injected liposomal Amp B
(L-Amp B) is taken up by the macrophage-rich organs such as the liver, spleen and
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lung (Lopez-Berestein, Rosenblum & Mehta, 1984; Ahmad, Sarkar & Bachhawat,
1990). Studies reported Lopez-Berestein et al. (1984) further suggested that the concen-
tration of Amp B was higher in lung and liver from infected animals vis a vis the
healthy controls.
Considering the importance of macrophages as primary defence cells in the control
of systemic fungal infection, we have studied the role of macrophages and polymorpho-
nuclear phagocytes (PMN cells) in controlling aspergillosis virulence and in reducing
the toxicity of L-Amp B. We have determined the effect of eliminating tissue macro-
phage/PMN cells from the liver and spleen by intravenous administration of liposomal
dichloromethylene diphosphonate (L-DMDP). Phagocytic uptake of the liposomes in
vivo by macrophages causes release of DMDP into the interior of the cell resulting in
cell death (van Rooijen, 1992). Intravenous administration of DMDP encapsulated in
liposome tends to eliminate, selectively and reversibly, macrophages from the spleen
and the liver without affecting the alveolar and other macrophages (Classen & van
Rooijen, 1984; van Rooijen, 1992).
The present communication compares the infectivity, toxicity, therapeutic efficacy
and tissue distribution of L-Amp B under in-vivo conditions in uninfected and in
diseased animals, with and without macrophage depletion.
Materials and methods
Chemicals
DMDP was a gift from Proctor Eaton Pharmaceuticals Inc. USA; Amp B and
cholesterol were purchased from Sigma Chemical Co., St Louis, USA; soya phosphati-
dylcholine (SPC) was from Dianorm, Munich, Germany; Fungizone, the commercial
deoxycholate preparation of Amp B, was obtained from Sarabhai Chemicals, Baroda,
India and was reconstituted in 5% dextrose before use. All other reagents used were of
analytical grade.
Animals
Male BALB/c mice (body wt 20-25 g) were obtained from the laboratory animal
facility of the Central Drug Research Institute, Lucknow, India and were maintained in
our animal house.
Animal model for aspergillosis in BALBjc mice
The animal model for aspergillosis in BALB/c mice was established as described by
Ahmad, Sarkar & Bachhawat (1989A). In brief, 1-8 x 107 Aspergillus fumigatus spores
suspended in sterile saline were injected intravenously into BALB/c mice via the tail
vein. In the case of macrophage depleted mice the spores were injected after 1 h of
L-DMDP treatment. Animals were also infected with a lower dose of fungal spores
(1-8 x 10*), both with and without macrophage depletion, to study the roles of PMN
and tissue macrophages in controlling aspergillosis virulence after infection with a
sublethal dose of A. fumigatus. Infection was confirmed by the presence of colony
forming units (cfu) in lung, liver, spleen and kidney tissues.
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Preparation of liposomes
DMDP-encapsulated liposomes were prepared as described by Claassen & van Rooijen
(1986) with the slight modification of using SPC instead of egg phosphatidylcholine. In
brief, 75 mg SPC and 19 mg cholesterol were dissolved in chloroform/methanol (2:1
v/v). The organic solvent was removed under reduced pressure in a rotary evaporator
and the resulting film was dessicated overnight. The thin dry film was hydrated in
10 mL of 10 mM phosphate buffered saline (pH 7-4) containing 1-89 g DMDP. The
preparation was kept for 2 h at room temperature under nitrogen and then sonicated
for 3 min at 20°C in a water bath sonicator. It was kept at room temperature for
another 2 h. The liposome suspension was centrifuged twice at 100,000 g for 30 min to
remove free, non-entrapped material and liposomes were finally resuspended in 4 mL
phosphate buffered saline.
Liposome-intercalated Amp B (1 mg Amp B for 45 mg total lipid), having the molar
lipid composition, SPC/cholesterol (7:3) was prepared and sonicated for 45 min as
described by Ahmad et al. (19896).
Depletion of phagocytic cells by liposomal dichloromethylene diphosphonate as studied
by transmission electron microscope
Male BALB/c mice were injected intravenously with liposome-encapsulated dichloro-
methylene diphosphonate. Twenty-four hours after the L-DMDP injection three mice
were killed and their lungs, livers and spleens were removed in cold, physiological
saline. The tissue samples were immediately immersed in fixative comprising 1%
paraformaldehyde, 2-5% glutaraldehyde in 01 M cacodylate buffer, pH 7-3. The tissues
were fixed for at least 4 h at 4°C, post-fixed in 1 % osmium tetroxide, dehydrated in a
graded series of ethanol solutions and then embedded in plastic resin. Thin sections
were stained with uranyl acetate (1%) and lead citrate (03%) and observed under CM
10 Philips transmission electron microscope at 80 Kv.
Determination of LDW of Amp B
L-DMDP was administered via the tail vein into 20 BALB/c mice. Twenty-four hours
later free Amp B (Fungizone, commercially available form, 0-5—4-0 mg/kg) was
administered to half of the animals and liposome-intercolated Amp B (10-80 mg/kg)
to the other half. Each set of 10 animals was split into four groups of BALB/c mice
(weight 20-25 g, five animals in each group). The logarithm of the successive dosage
levels differed by a constant d, such that the geometric factor (R) is related to d by the
relation d = log R. Survival was checked over a period of 4 days. Median lethal doses
(LDJO) were calculated by the formula log ( L D ^ = log dose (minimum)-flog ratio
(/"+ 1), as described by Weil (1952). The confidence level of the assay was 5%. For LD*,
determination of liposome-intercalated Amp B, without macrophage depletion, mice
were injected with 2-5-200 mg/kg body weight. An approximate test of the significance
of difference between the two LD^ values was made by using the test criteria:
Zo = mf—m2
S.E.(mt — /Mj)
where m, and m2 are the LD^ values with and without macrophage depletion and
S.E.(W, -m2) is the standard error of their difference. This is obtained as s.E.(m, — m2) =
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Var. mx +Var. m2 where Variance m, = m] Var. (/",), d\ where d[ — log,0 /? (common
ratio of the doses) and/ , is a function of the mortality number in a given sequence as
available in the tables of Weil (1952). Similarly, for set 2 the suffixes 2 are used in the
corresponding quantities to obtain Var. (mj. The difference is deemed significant at the
5% level if Z is greater than 1-96 (normal distribution) and at 1% level if Z is greater
than 2-58.
Treatment of infected mice with and without macrophage depletion
BALB/c mice were injected via the tail vein with 0-2 mL of L-DMDP, followed 1 h
later by the administration of 1-8 xlO7 A.fumigatus spores. Animals were divided
randomly into two groups of 20 animals each. Twenty-four hours after infection
animals in one group were injected with L-Amp B (05 mg/kg); the other group was left
untreated. For survival experiments, ten animals were used in each experiment. The
same protocol described above was followed. Survival was also checked in groups of
animals which received only L-DMDP and in groups of animals to which were
administered L-DMDP and L-Amp B (05 mg/kg).
The effect of L-Amp B was evaluated from the survival of animals, together with the
number of cfus in lung, liver, spleen and kidney tissues. Survival was checked for up to
7 days after therapy with L-Amp B. To study the fungal load and numbers of cfus in
lung, liver, spleen and kidney were determined as follows: three animals from each
group were killed on alternate days after therapy and their lungs, livers, spleens and
kidneys were excised aseptically, weighed and homogenized in 10 mL sterile 0 1 5 M
NaCl. A 25-fold dilution was made and aliquots were plated on Sabouraud Dextrose
medium. Colonies were counted after 48 h incubation at 37°C.
Statistical analysis of cfu and survival counts
Statistical analysis of the cfu values was done by using the student f-test to compare
two mean values with equal frequencies as given by Snedecor & Cochran (1968). The
survival data were analysed by using the x2 test of 2 x 2 table by Yate's correction of the
Chi-Square, as well as by the Fisher's exact test.
Determination of amphotericin B in liposomes and in various organs
L-Amp B was determined both spectrophotometrically at 405 nm and by high
performance liquid chromatography (HPLC) at 345 nm. The intercalation efficiency
was found to be greater than 90%. HPLC analysis of Amp B in various organs and
serum was done according to the method of Nilsson-Ehle et al. (1977), modified as
reported earlier (Ahmad et al., 1989Z>). The recovery of Amp B from various tissues
ranged from 60-75%. The recovery of Amp B from various tissues ranged from 60-
75%. The recovery from serum was more than 95%. Recovery of Amp B from serum
was assessed as follows: blood samples drawn from the hearts of five mice were pooled
and the mixture was allowed to clot. It was centrifuged to obtain serum. Pooled serum
(0-5 mL) was homogenized with I mL of methanol containing 10-20 ng of Amp B and
centrifuged at 12,000 g for 15 min. Samples (20 fiL) of the supernatant were injected
into a C,8 reverse phase column for HPLC analysis.
Amp B levels were determined in normal and infected animals, killed 1 and 24 h,
respectively, after iv administration of L-Amp B (2 mg/kg). L-DMDP was adminis-
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tered 1 h before administration of fungal spores and L-Amp B was injected 24 h after
administration of fungal spores. For tissue distribution analysis, groups of six mice
were killed; blood and organs (lung, liver, spleen and kidney) were removed, pooled
and frozen until required for analysis. The amount of Amp B in various organs was
determined. Final values were calculated by adjusting the measured value to take
account of the recovery factors.
Results
Depletion of phagocytic cells by liposomal dichloromethylene diphosphonate as studied
by transmission electron microscope
Electron microscope studies show that 24 h after L-DMDP treatment the macro-
phage/PMN cell populations in the liver and the spleen were almost completely
depleted and the few remaining cells were undergoing degenerative changes, as
indicated by the appearance of a pycnotic nucleus, as well as a highly vacuolated
cytoplasm (Figures 1 and 2(a)). The multilobed nuclei of PMN cells from the liver and
spleen were also seen to be undergoing degenerative changes and the cells showed the
presence of large cytoplasmic inclusions (Figures I and 2(b)). The alveolar macro-
phage/PMN cells (Figure 3(a), (b)) however, showed no degenerative changes 24 h
after L-DMDP administration and displayed well denned nuclei and dense phagocytic
granules.
MS
(a) (b)
Figure I. Electron micrographs of (a) a degenerating macrophage from liver showing cytoplasmtc
vacuohzation indicating degenerative process ( x8900). 24 h after treatment with L-DMDP. (b) A degener-
ating PMN and macrophage (M) from liver after 24 h of L-DMDP treatment. The multi-lobed nucleus of the
PMN displays degenerative changes and cytoplasmic vacuolization Macrophage (M) nucleus appears
pycnotic ( x 6600).
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Figure 2. Electron micrographs of (a) a degenerating PMN from spleen, 24 h after L-DMDP treatment
Note pycnotic nucleus and vacuolated cytoplasm ( x 8900) (b) A degenerating PMN from spleen. 24 h after
treatment with L-DMDP showing remnants of a necrotic cell ( x 5200).
Infeclivity
Animals which received a lower dose (1-8 x 106) of fungal spores showed similar fungal
loads in various organs irrespective of macrophage depletion. In macrophage-depleted
animals, the lungs and kidneys were more infected while in animals with normal
macrophage populations these organs showed lower fungal counts (Table I). The
fungal load was seen to decrease to negligible values in all organs after 6 days in the
case of animals without macrophage depletion (100% survival after the sixth day of
infection). In contrast, macrophage-depleted mice showed 100% mortality 3 days after
fungal spore challenge (Table I). In the case of animals infected with 1-8 xlO7
A.fumigatus spores disseminated fungal infection was observed in both control and
macrophage-depleted mice (Table II). Since disseminated fungal infection was observed
Table I. Fungal load" (cfu/organ) in various organs of BALB/c mice infected with A.fumigatus
Days
Expt. L-DMDP after
No. treatment infection Lung Liver Spleen Kidney
la - 2 4OOO±70O* 40,000±2800 200.000 ±28,000 4000±1400''
l b - 6 25±5-4 20O±45 2 5 ± 6 5 0 ± l l
2a + 2 8000±1400* 35,000±2400 150,000 ± 14,000 9000±IO(Ky
2b + 100% mortality 3 days after fungal challenge
"Values are expressed as mean error±s.E. of means of cfu counts from duplicate readings from three
animals, i.e. six observations.
^Significant differences at the 5% level between (la) and (2a).
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(a) (b)
Figure 3. Electron micrographs of (a) a normal PMN cell from the lung after 24 h of L-DMDP treatment.
Note the well defined multilobed nucleus and presence of phagocytic granules (x 8900) (b) A normal
macrophage from lung 24 h after L-DMDP treatment (x 11,500).
both with and without macrophage depletion after inoculation with 18 x 107 fungal
spores, this dose was used in all subsequent experiments.
LDy, of L-Amp B
The LDjo values of various liposomal formulations are given in Table III. As evident
from Table III there was a 2-6-fold increase in the toxicity of L-Amp B with L-DMDP
Table II. Fungal load (cfu/organ) in various organs of A. fumigatus infected BALB/c mice given
liposomal amphotericin B therapy
Group"
No.
1
2
3
4
Days
after
infection
2
2
4
6
®
2
Days
after
L-Amp B
therapy
no
L-Amp B
therapy
1
3
•s
7
no
L-Amp B
therapy
1
L-DMDP
treatment lung
120±4
3-80+1-7
1 -20 ± 0
0-20 + 0-1
0-17±0
+ 350±2l
+ 120±35
cfu (
liver
388 ±62
30 + 3-8
8-2 ±3-8
1 -4 ± 1 -0
0
273 ±139
690± 15
x!03)
spleen
620 ±90
190 ±8-3
2-50± 1-7
010±003
0-05 ±0-03
32-O±14
22-5 ±7
kidney
7-20 ±0-4
3-70+1-8
0-70+ 01
0
0
20-0 ±7-0
120 ±3-5
'L-DMDP was administered to groups 3 and 4 only.
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Table III. LD,,, of various formulations of
Amp B, with and without administration of
L-DMDP, for BALB/c mice
Drug
formulation L-DMDP
Fungizone —
Fungizone +
L-Amp B -
L-Amp B +
1-2"
1-4*
9-5°'
3-7*'
"•^Significant differences (1% level).
treatment, as compared with the untreated animals. On the other hand, macrophage
depletion had no effect on the toxicity of Fungizone.
Survival of infected animals after L-Amp B therapy with and without macrophage
depletion
The survial patterns of various groups of animals are shown in Figure 4. All uninfected
animals were alive after the seventh day of administration of either L-DMDP or
L-DMDP followed by L-Amp B (0-5 mg/kg) (not shown in Figure 4). In the absence of
L-Amp B therapy, infected animals (with no macrophage depletion) survived for up to
2 days of infection (100% survival), while the macrophage-depleted animals showed
70% mortality during the same period. In the case of infected animals given L-Amp B
Days after therapy
Figure 4. Survival of infected BALB/c mice with and without L-DMDP administration: O- untreated
controls; # . macrophage depleted, untreated: V. infected mice. L-Amp B therapy: V . infected and
macrophage depleted mice. L-Amp B therapy. Values are expressed as mean of % survival of animals of two
separate experiments and the vertical bars represent standard error of means at each time point.
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therapy, the survival of animals with and without macrophage depletion was found to
be 70% and 100%, respectively, one day after L-Amp B therapy. While 80% of the
infected animals not subject to macrophage depletion and given L-Amp B treatment
survived for at least 7 days, those mice with macrophage depletion had a 100%
mortality rate during the same time period, even with L-Amp B therapy. The chi-
squared test revealed that the survival ratios were heterogenous, as indicated by the
significant (1% level) values for each. The Yates' correction of the chi-squared and
Fischer's exact test were found to be significant after the fourth day (5% level) within
the groups.
Cfu in various organs of infected BALB/c mice after liposomal therapy with and
without macrophage depletion
Table II shows the effect of L-Amp B therapy in reducing the fungal load in the lungs,
livers, spleens and kidneys of infected mice. Disseminated fungal infection was
observed both with and without macrophage depletion after 2 days of fungal infection.
In infected animals without macrophage depletion and which were given L-Amp B
therapy there were marked reductions in fungal counts in all organs after 1 day of
therapy. However, in macrophage-depleted mice, which were given L-Amp B therapy,
the cfu count was consistantly high in all organs after 1 day of therapeutic treatment.
Tissue distribution pattern of L-Amp B in normal and infected mice with and without
macrophage depletion
The organ concentrations of Amp B, following the administration of L-Amp B, in
uninfected mice at 1 h and 24 h, with and without macrophage depletion, are shown in
Table IV. Tissue distribution studies revealed marked increases in the concentrations of
Amp B in the lungs, spleens, kidneys and sera of macrophage-depleted animals; in
contrast, there was a decrease in the liver. The most significant increase (6-6-fold) in the
concentration of Amp B in mice with macrophage depletion was observed in the
spleen. Twenty-four hours after the administration of L-Amp B there were increases in
the concentration of Amp B in the lungs (33-fold), spleens (3-2-fold) and kidneys
(1-4-fold) of macrophage-depleted mice as compared with control values, i.e. in organs
of mice not subject to macrophage depletion.
Table IV. Organ concentration of Amp B following
intravenous administration of L-Amp B to normal mice, with
and without administration of L-DMDP
Organ (/ig Amp B/g tissue) and serum
(mg Amp B/L) concentration of Amp B
without L-DMDP with L-DMDP
I h 24 h I h 24 h
Lung
Liver
Spleen
Kidney
Serum
N.D., Not
4-5 ±0-7
7-6 ±1-4
3-5 ±0-7
l-3±0-42
0-81014
detectable.
3-210-28
14-710-7
4010-28
4-310-28
0-610-14
9-110-28
6-210-28
23-311-4
3-710-98
3-510-42
10-711-4
7-711-4
12-711-4
6-2 + 0-56
N.D.
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Table V. Organ concentration of Amp B (mean±s.D.)
following intravenous administration of L-Amp B to infected
mice, with and without administration of L-DMDP
Organ (jig Amp B/g tissue) and serum
(mg Amp B/L) concentration of Amp B
without L-DMDP with L-DMDP
1 h 24 h 1 h 24 h
Lung
Liver
Spleen
Kidney
Serum
N.D., Not
7-7 ±0-28
52-5+ 2-1
8-4 ±1-4
0-3 + 0-07
0-6±0-14
detectable.
1-2 ±0-28
31-2+1-4
21 ±0-35
3 1 ±0-42
O5±014
ll-OiO-10
5-7 + 0-98
22-7 ±1-4
5-5 ±042
8-6 + 0-56
6-6 ±0-56
7-9 + 0-28
16 3± 1-4
3-9+1-4
N.D.
It is evident from Table V that there was a marked alteration in the tissue distribu-
tion of Amp B during infection at 1 h and 24 h after drug administration to macro-
phage-depleted animals. In spleen (2-7-fold), kidney (180-fold) and serum (140-fold)
the concentrations of Amp B were significantly enhanced by macrophage depletion,
whereas there was a significant decrease in the concentration of Amp B in the liver
(9-2-fold), in comparison with animals without macrophage depletion. Tissue distribu-
tion of L-Amp B in infected animals after 24 h followed a similar pattern to that
observed in uninfected mice with macrophage depletion. Increases in the concentration
of Amp B were observed in the lungs (5-5-fold), spleens (7-8-fold), kidneys (1-2-fold)
while a decrease was noted in the liver (3-9-fold), as compared with mice without
macrophage depletion.
Discussion
The results presented in this paper demonstrate that depletion of PMN and resident
macrophages from liver and spleen accentuates both the virulence of aspergillosis and
the toxicity of liposomal Amp B. The therapeutic index of L-Amp B is also greatly
reduced, as inferred from the poor survival of macrophage/PMN-depleted mice after
aspergillosis challenge.
van Rooijen and co-workers have shown histochemically depletion of macrophages
in both the liver and the spleen 24 h after iv administration of L-DMDP (van Rooijen
& Nieuwmegen, 1984); this was also confirmed ultrastructurally in the spleen (van
Rooijen, Nieuwmegen & Kamperdijk, 1985). Our electron microscope studies are in
agreement with the ultrastructural studies of van Rooijen et al. (1985) on the elimina-
tion of macrophages from the spleen and confirm the depletion of macrophages in the
liver. Our ultrastructural studies also show depletion of PMN cells from the liver and
the spleen 24 h after administration of intravenous L-DMDP. Furthermore, in agree-
ment with the findings of van Rooijen (1992) macrophages in the lung were not affected
by L-DMDP treatment and neither were PMN cells.
The increased virulence of A.fumigatus in macrophage/PMN-depleted animals is
evident from the fact that when a sublethal dose of fungal spores was injected into these
animals they did not survive for more than 2 days after infection. In contrast, in
similarly challenged animals without macrophage depletion the fungal count after 6
days showed a marked decrease and all the animals survived. It is well known that
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macrophages phagocytize fungal cells during systemic infection. Studies have shown
that tissue macrophages play a key role in the control of infectivity of intracellularly
growing pathogens, e.g. Listeria monocytogenes (Pinto et al., 1991). The results in this
study show that tissue macrophages and PMN cells play an important role in the
control of aspergillosis virulence, although A. fumigatus is not an intracellular
pathogen.
Liposomal Amp B is primarily known to be taken up by the reticuloendothelial
system and the drug accumulates in lung, liver and spleen tissues of infected animals
(Lopez-Berestein, et al., 1984). The importance of PMN cells and resident macrophages
in the control of fungal disease is evident from the fact that there was an 80% survival
after 7 days of infected animals which had been given L-Amp B therapy, while for
macrophage-depleted animals there was 100% mortality of infected animals after one
day of L-Amp B therapy. The importance of macrophages/PMN cells is further
supported by our data on fungal load in animals which were given L-Amp B therapy.
In infected animals, subsequently given L-Amp therapy, there were marked reductions
in fungal counts in all organs. However, in the case of macrophage-depleted mice
treated with L-Amp B, the fungal counts did not decline after therapy and, as a
consequence the drug therapy was ineffective.
Comparative toxicity studies with L-Amp B and Fungizone indicated that, in contrast
to free Amp B, there was a marked increase in the toxicity of L-Amp B in macro-
phage/PMN-depleted mice. The increase in circulation time of L-Amp B may give
greater opportunity for the drug to interact with potentially sensitive cells resulting in
enhanced toxicity (Szoka, Milholland & Barza, 1987). It is interesting to note that the
concentration of Amp B in the kidneys of macrophage-depleted animals was found to
be comparable to that observed for Fungizone in a previous study (Ahmad et al.,
1989/>). This increase could also be one of the factors responsible for the enhanced
toxicity, as well as for the poor therapeutic efficacy, of L-Amp B.
Tissue distribution of L-Amp B in uninfected mice, with and without macrophage
depletion, followed essentially the same pattern as that reported by Claassen & van
Rooijen (1984). However, there was a dramatic change in the tissue distribution of
L-Amp B in infected mice, with and without macrophage depletion. As expected a
marked increase in the levels of Amp B was observed in all the infected organs, except
liver. These findings support our contention that PMN cells and resident macrophages
have major roles to play in the capture of the drug in the diseased tissues, enhancing
thereby its effectiveness against the fungus. In the present study, we observed an
increase in the concentration of Amp B in the spleen, even though L-DMDP treatment
results in the depletion of splenic macrophages. This could possibly be due to the
phagocytic activity of other cells, such as the sinus lining cells of the spleen, which have
been shown to assume part of the phagocytic function (Claassen & van Rooijen, 1984).
This functional capability has not been observed in liver. The increase in the concentra-
tion of Amp B in circulation in macrophage-depleted mice could also be due, in-
directly, to the depletion of resident macrophages and PMN cells from the liver and the
spleen.
In conclusion, our observations on in-vivo toxicity, therapeutic efficacy and tissue
distribution profile of L-Amp B in BALB/c mice, with and without macrophage
depletion, suggest that resident macrophages and PMN cells have important roles in
the containment of aspergillosis virulence, although A. fumigatus is not an intracellular
pathogen. Also, resident macrophages/PMN cells play a pivotal role in the uptake of
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liposomal Amp B from serum, which may account for the decreased toxicity of the
drug.
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